Tiziana Life Sciences PLC’s (TLSA) Lock-Up Period Will End on May 20th

Tiziana Life Sciences’ (NASDAQ:TLSA) lock-up period will end on Monday, May 20th. Tiziana Life Sciences had issued 442,910 shares in its IPO on November 20th. The total size of the offering was $4,384,809 based on an initial share price of $9.90. After the expiration of the company’s lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

NASDAQ TLSA opened at $8.34 on Friday. Tiziana Life Sciences has a 12 month low of $5.00 and a 12 month high of $12.17.

A hedge fund recently raised its stake in Tiziana Life Sciences stock. HighTower Advisors LLC increased its stake in Tiziana Life Sciences PLC (NASDAQ:TLSA) by 54.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 591,163 shares of the company’s stock after buying an additional 208,100 shares during the quarter. HighTower Advisors LLC owned approximately 4.60% of Tiziana Life Sciences worth $3,578,000 as of its most recent SEC filing. Institutional investors and hedge funds own 3.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Tiziana Life Sciences PLC’s (TLSA) Lock-Up Period Will End on May 20th” was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.thelincolnianonline.com/2019/05/17/tiziana-life-sciences-plcs-tlsa-lock-up-period-will-end-on-may-20th.html.

About Tiziana Life Sciences

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus.

Featured Article: How a Strangle Strategy is different from a Straddle Strategy

Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.